A Comparison of Patient-Reported Health-Related Quality of Life During Proton Versus Photon Chemoradiation Therapy for Esophageal Cancer
Aurélie Garant(The University of Texas Southwestern Medical Center), Christopher L. Hallemeier(Mayo Clinic in Arizona), Terence T. Sio(The University of Texas MD Anderson Cancer Center), Thomas J. Whitaker(Mayo Clinic), William G. Rule(Mayo Clinic in Arizona), David M. Routman(Mayo Clinic in Arizona), William S. Harmsen(Mayo Clinic), Harry H. Yoon(Mayo Clinic), E. Tryggestad(Mayo Clinic), Shanda H. Blackmon(The University of Texas MD Anderson Cancer Center), Michael G. Haddock(Mayo Clinic in Arizona), T.J. Wilhite(Mayo Clinic), Kenneth W. Merrell(Mayo Clinic), Jonathan B. Ashman(Mayo Clinic in Arizona), Grant M. Spears(Mayo Clinic in Florida), James A. Martenson(Mayo Clinic), Michelle A. Neben Wittich(Mayo Clinic)
Cited by 25
Related Papers
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
|JAMA Oncology|2018|1.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)
|Journal of Clinical Oncology|2008|270